Lantern Pharma: Transforming Cancer Drug Development with A.I.
Mar. 29, 2021
Lantern Pharma (Nasdaq: LTNR) is a clinical stage biotechnology company leveraging its RADR® artificial intelligence (“A.I.”) platform to transform the pace, risk and cost of oncology drug development. RADR® A.I. quickly and efficiently develops precise genetic signatures of disease that underpin the identification of patients for whom its portfolio of oncology drug candidates is likely to have the greatest therapeutic effect. Lantern is currently developing three drug candidates in solid tumors. Two are in phase 2 development: LP-300 for non-small cell lung cancer (NSCLC) in never smokers and, LP-100 for metastatic hormone-refractory prostate cancer. The third, LP-184 is perhaps most valuable due to its well-defined response is a range of genetically-defined solid tumors. LP-184 is currently in pre-clinical studies in collaboration with world-renowned cancer institutes across several tumors, including: glioblastoma (GBM), pancreatic cancer, prostate cancer and site-agnostic tumors that overexpress a specific genetic biomarker (“PTGR1”). Recently initiated collaboration to develop Antibody Drug Conjugate (ADCs) further expands the range of potential tumor targets for Lantern’s portfolio of highly targeted precision oncology drug candidates.
